REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
01/06/2025
Voltar para busca
Dado oficial do USPTO
LEAFBIO
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
41
Atualização mais recente
02/06/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42
Data de depósito
22/08/2012
Data de registro
31/05/2016
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
30/11/2022
Última transação
02/06/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
702
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
01/01/2013
Primeiro uso no comércio
01/01/2013
Código do desenho
4
Tipo de titular
03
Localização do titular
San Diego, CA
Examinador
WILKE, JOHN
Unidade examinadora
L40
Localização atual
TMEG LAW OFFICE 104
Titulares e representantes
Titulares
LeafBio, Inc.
Representantes
Paul Nardulli OPTIMA LAW GROUP, APC
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Diagnostic reagents for scientific or research use; Diagnostic kits consisting primarily of monoclonal antibodiesbuffersreagents to monitor toxicity of drugs; Diagnostic reagents for clinical or medical laboratory use; Diagnostic reagents for in vitro use in biochemistryclinical chemistry and microbiology; Diagnostic reagents for scientific or research use; Laboratory chemicalsan antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; Reagent for chemical analysis; Reagents for research purposes; Reagents for scientific or medical research use; Reagents for testing the sterility of pharmaceuticals and injectable solutions; Reagents for use in scientific apparatus for chemical or biological analysis; Reagents for use in biodefense
Classe 5
Pharmaceutical products for use in the treatment and prevention of cardiovascular diseases and disorderscentral nervous system and neurological diseases and disordersurological diseases and disordersviral and infectious diseasescancergastrointestinal diseases and disordersmusculoskeletal diseases and disordersmigraines and headachespainhypertensioninflammation and inflammatory diseases and disordersmetabolic diseases and disordersrespiratory and infectious diseases and disordersimmunologicalbacterialviral and fungal diseases and disorderspsychiatric diseases and disordersasthmaallergiesdiabetesobesitystrokeerectile and sexual dysfunctionsexually transmitted infections includingbut not limited toHIVHPVherpeshemolytic diseases and disorders; Pharmaceutical preparationscholesterol preparationsosteoporosis preparationsoncological preparationsdermatological preparationsurological preparationsophthalmologic preparationstissue and skin repair preparations and gynecological preparations ; Pharmaceuticalsanti-infectives; Diagnostic kits consisting primarily of monoclonal antibodiesbuffersreagents for use in disease testing; Medical diagnostic reagents; Medical diagnostic reagents and assays for testing of body fluidsincluding for microorganisms; Drug delivery agents consisting of compounds that facility delivery of a wide range of pharmaceuticals; Antibacterial pharmaceuticals; Cardiovascular pharmaceuticals; Contraceptive foamsspongespreparations; Oral contraceptives; Pharmaceutical products for use in biodefense
Classe 42
Pharmaceutical research and development; research and development of pharmaceutical preparations for the treatment and prevention of cardiovascular diseases and disorderscentral nervous system and neurological diseases and disordersviral and infectious diseasescancerurological diseases and disordersgastrointestinal diseases and disordersmusculoskeletal diseases and disordersmigraines and headachespainhypertensioninflammation and inflammatory diseases and disordersmetabolic diseases and disordersrespiratory and infectious diseases and disordersimmunologicalbacterialviral and fungal diseases and disorderspsychiatric diseases and disordersasthmaallergiesdiabetesobesitystrokeerectile and sexual dysfunctionsexually transmitted infections includingbut not limited toHIVHPVherpes and hemolytic diseases and disorders; research and development of pharmaceutical preparationscholesterol preparationsosteoporosis preparationsoncological preparationsdermatological preparationsurological preparationsophthalmologic preparationstissue and skin repair preparations and gynecological preparations ; research and development of drug delivery devices; medical and scientific researchconducting clinical trials; Consulting services in the fields of biotechnologypharmaceutical research and developmentlaboratory testingdiagnosticspharmacogenetics; Development of pharmaceutical preparations and medicines; Pharmaceutical drug development; Pharmaceutical research and development services; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing reagent sample testing and diagnostic services for others in the fields of science and research related thereto; Pharmaceutical research and development in relation to biodefense
Publicações
Histórico de despachos e eventos da marca no USPTO.
41 publicações encontradas
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
30/11/2022
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
30/11/2022
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
17/11/2022
E815
TEAS SECTION 8 & 15 RECEIVED
12/05/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
31/05/2016
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE MAILED
26/04/2016
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
23/04/2016
SUPC
STATEMENT OF USE PROCESSING COMPLETE
16/04/2016
IUAF
USE AMENDMENT FILED
17/03/2016
EISU
TEAS STATEMENT OF USE RECEIVED
17/03/2016
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
29/09/2015
EX5G
SOU EXTENSION 5 GRANTED
27/09/2015
EXT5
SOU EXTENSION 5 FILED
09/09/2015
EEXT
SOU TEAS EXTENSION RECEIVED
09/09/2015
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
04/04/2015
EX4G
SOU EXTENSION 4 GRANTED
03/04/2015
EXT4
SOU EXTENSION 4 FILED
20/03/2015
EEXT
SOU TEAS EXTENSION RECEIVED
20/03/2015
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
02/10/2014
EX3G
SOU EXTENSION 3 GRANTED
01/10/2014
EXT3
SOU EXTENSION 3 FILED
19/09/2014
EEXT
SOU TEAS EXTENSION RECEIVED
19/09/2014
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/06/2014
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
18/04/2014
EX2G
SOU EXTENSION 2 GRANTED
17/04/2014
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
14/04/2014
EXT2
SOU EXTENSION 2 FILED
20/03/2014
EEXT
SOU TEAS EXTENSION RECEIVED
20/03/2014
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
26/09/2013
EX1G
SOU EXTENSION 1 GRANTED
24/09/2013
EXT1
SOU EXTENSION 1 FILED
24/09/2013
EEXT
SOU TEAS EXTENSION RECEIVED
24/09/2013
NOAM
NOA MAILED - SOU REQUIRED FROM APPLICANT
26/03/2013
PUBO
PUBLISHED FOR OPPOSITION
29/01/2013
NPUB
NOTICE OF PUBLICATION
09/01/2013
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/12/2012
DOCK
ASSIGNED TO EXAMINER
15/12/2012
MPMK
NOTICE OF PSEUDO MARK MAILED
31/08/2012
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
30/08/2012
NWAP
NEW APPLICATION ENTERED
25/08/2012
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace LEAFBIO ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.